Drug Type Small molecule drug |
Synonyms |
Target |
Action antagonists, inhibitors |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists), Raf kinase inhibitors(RAF serine/threonine protein kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | 26 Oct 2022 | |
| Solid tumor | Preclinical | China | 26 Oct 2022 |





